Cargando…
Decitabine: a historical review of the development of an epigenetic drug
The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem...
Autores principales: | de Vos, Dick, van Overveld, Wendy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103145/ https://www.ncbi.nlm.nih.gov/pubmed/16220311 http://dx.doi.org/10.1007/s00277-005-0008-x |
Ejemplares similares
-
Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015) -
Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine
por: Lim, Sue Ping, et al.
Publicado: (2013) -
Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue
por: Traube, Franziska R., et al.
Publicado: (2022) -
Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019) -
Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
por: Halaban, Ruth, et al.
Publicado: (2009)